Re: Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines

European Urology

Volumn 64, Issue 1, 2013, Pages 169-170

  Schrader, Andres J ^a   Schrader, Mark G ^a   Cronauer, Marcus V ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; ANDROGEN RECEPTOR; ANDROGEN RECEPTOR SPLICE VARIANT; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; DRUG DERIVATIVE; ISOPROTEIN; PHENYLTHIOHYDANTOIN;

CANCER HORMONE THERAPY; CANCER INHIBITION; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL PROLIFERATION; DRUG EFFICACY; HUMAN; NOTE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; GENETICS; MALE; PROSTATE TUMOR; ANALOGS AND DERIVATIVES; PROSTATIC NEOPLASMS;

HUMANS; MALE; PHENYLTHIOHYDANTOIN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; RECEPTORS, ANDROGEN;

EID: 84878876130     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.04.024     Document Type: Note

References (7)

1. P.A. Watson, Y.F. Chen, and M.D. Balbas Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor Proc Natl Acad Sci U S A 107 2010 16759 16765
2. W. Streicher, F. Zengerling, and M. Laschak AR-Q640X, a model to study the effects of constitutively active C-terminally truncated AR variants in prostate cancer cells World J Urol 30 2012 333 339
3. S. Sun, C.C. Sprenger, and R.L. Vessella Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant J Clin Invest 120 2010 2715 2730
4. R. Hu, C. Lu, and E.A. Mostaghel Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer Cancer Res 72 2012 3457 3462
5. E. Ileana, Y. Loriot, and L. Albiges Abiraterone in patients with metastatic castration-resistant prostate cancer progressing after docetaxel and MDV3100 [abstract 4554] J Clin Oncol 30 2012 290s
6. F. Zengerling, W. Streicher, and A.J. Schrader Effects of sorafenib on C-terminally truncated androgen receptor variants in human prostate cancer cells Int J Mol Sci 13 2012 11530 11542
7. R.J. Andersen, N.R. Mawji, and J. Wang Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor Cancer Cell 17 2010 535 546